Carvasin

Quick links to important sections

Carvasin

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carvasin

Property Description
Active Ingredient Isosorbide Mononitrate
Form Oral tablets or capsules (Immediate and extended-release)
Pharmacological Class Organic Nitrate / Vasodilator
Common Use Preventative management of Angina Pectoris
Origin Synthetic (Chemically manufactured)

Overview of the Medication

Carvasin is a trade name for the prescription drug containing Isosorbide Mononitrate, an active substance recognized as an organic nitrate and vasodilator. This medication is formulated for oral administration and is distinguished by its role in providing sustained, long-term management rather than acute relief. Its chemical properties are characterized by structural integrity and predictable action.

Composition and Origin

The foundation of Carvasin is the primary active ingredient, Isosorbide Mononitrate. This active pharmaceutical ingredient (API) is synthetic, meaning it is manufactured through specialized chemical synthesis, and is not derived from natural sources. The final product combines this synthetic API with pharmacologically inert excipients that ensure the proper stability and reliable release of the medication once consumed.

General Therapeutic Purpose

Carvasin is indicated for the prophylactic (preventative) and chronic treatment of symptoms related to Angina Pectoris (chest pain caused by reduced blood flow to the heart). Its therapeutic goal is to reduce the overall frequency and severity of future anginal episodes, establishing a foundational regimen for heart health. As a maintenance therapy, this medication is designed for routine scheduling and is not intended for the quick resolution of an acute, sudden episode of chest pain.

What side effects are possible with Carvasin?

Possible Side Effects and Safety Information

The safety profile for Carvasin (Isosorbide Mononitrate) is officially documented by government regulatory sources, including the U.S. NIH DailyMed and the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC). The documented adverse effects are primarily related to the medication's action as a vasodilator.

Documented Adverse Reactions and Frequencies

Adverse reactions are classified by frequency as listed in regulatory documents:

Frequency Classification System-Organ Class Adverse Reaction
Very Common (ge 1/10) Nervous System Disorders Headache
Common (ge 1/100 to < 1/10) Vascular Disorders Hypotension (Low Blood Pressure)
Nervous System Disorders Dizziness
Gastrointestinal Disorders Nausea
Uncommon Cardiac Disorders Tachycardia (Increased Heart Rate)
Nervous System Disorders Syncope (Fainting)

The most frequent reaction, Headache, is often noted in labeling as a transient effect that is more likely at treatment initiation and typically subsides with continued use.

Serious Safety Considerations and Restrictions

Regulatory documents highlight the potential for severe Hypotension leading to Syncope as a clinically significant safety concern. Furthermore, an exacerbation or worsening of Angina Pectoris has been reported with an unknown frequency.

Use of Isosorbide Mononitrate is officially contraindicated (must not be used) in patients with specific pre-existing conditions where its effects could be dangerous, including Marked Hypotension, Severe Anemia, and Circulatory Failure (such as shock or collapse).

Overdose and Emergency Response

An overdose of Carvasin (Isosorbide Mononitrate) is officially documented to stem from profound vasodilatation. The resulting manifestations listed in regulatory information include severe hypotension (low blood pressure), a throbbing headache, vertigo, syncope (fainting), nausea, vomiting, and excessive perspiration.

Regulators classify an overdose as having the potential for severe, life-threatening outcomes. These include persistent severe hypotension, circulatory collapse (vascular collapse), and the risk of Methaemoglobinaemia, a serious haematological complication associated with symptoms like cyanosis. A rise in intracranial pressure may also occur.

Emergency medical attention is required immediately upon any suspicion of overdose. Patients must call emergency services or contact a Poison Control Center.

Official regulatory guidance details the necessary supportive management. Treatment measures include attempts to correct severe hypotension by intravenous fluid administration and raising the foot of the bed. Observation and monitoring of blood pressure and pulse for at least 12 hours are mandated. The specific treatment for documented Methaemoglobinaemia is Methylene blue. Caution is noted in patients with renal disease or congestive heart failure during supportive care.

Therapeutic Uses of Carvasin

What Carvasin Treats: Main Uses and Benefits

Carvasin, containing Isosorbide Mononitrate, is generally used to manage symptoms related to physical discomfort associated with Angina Pectoris. This medication is indicated for the prevention and long-term management of Angina Pectoris due to Coronary Artery Disease. It is a commonly used medication, not applied in acute symptomatic episodes.

The therapeutic focus is on prophylaxis (prevention) for conditions involving episodic or fluctuating manifestations, such as recurring chest pain, pressure, and tightness. It provides support that may help ease the overall symptom burden by contributing to managing the recurrence and intensity of episodes over time.

“The long-term therapy may assist with maintaining a sense of stability when symptoms are more noticeable.”

This application is relevant in clinical settings that involve chronic management of conditions presenting with significant symptomatic burden. By assisting with managing these recurrent symptom patterns, the treatment may help improve day-to-day comfort during periods of heightened symptoms.


Quick Fact: Supportive Management for Recurrent Chest Discomfort

Type of Use Primary Indication Patient Benefit
Prophylactic Stable Angina Pectoris Contributes to easing the overall symptom load

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

Carvasin, containing Isosorbide Mononitrate, is officially approved for use by adults for the prophylactic treatment of Angina Pectoris. Regulatory agencies strictly define populations who must not use the medication (contraindications).

Contraindicated Populations

Use is absolutely contraindicated for patients with a known hypersensitivity to any nitrate compound. It must not be used concurrently with Phosphodiesterase Type 5 (PDE-5) inhibitors (e.g., sildenafil) or the soluble Guanylate Cyclase (sGC) stimulator riociguat due to the risk of severe, life-threatening hypotension. Absolute contraindications also include patients experiencing cardiogenic shock, acute circulatory collapse, severe hypotension (systolic BP leq 90 mmHg), severe anaemia, and certain structural heart conditions like aortic stenosis.

Restricted and Non-Recommended Use

Use is not recommended for the paediatric population as safety and efficacy have not been established. Similarly, use during pregnancy and lactation is generally not recommended due to insufficient data. Older adults may be more susceptible to hypotension, requiring special care. Caution is also advised for patients with severe liver or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Carvasin (Isosorbide Mononitrate) defines several classifications of interaction risk, primarily related to its core function as a vasodilator.

Absolute Regulatory Contraindication

Co-administration with Phosphodiesterase Type 5 (PDE-5) Inhibitors (such as sildenafil or tadalafil) and the Soluble Guanylate Cyclase (sGC) Stimulator Riociguat is formally prohibited. These combinations carry a documented high risk of severe hypotension and associated cardiovascular complications.

Pharmacodynamic Potentiation

The blood pressure-lowering effect is potentiated by other medicinal product categories, leading to an additive hypotensive effect. This includes most antihypertensive agents such as beta-blockers, calcium channel blockers, diuretics, ACE inhibitors, and certain Neuroleptics or Tricyclic Antidepressants. The consumption of Alcohol is also associated with an additive vasodilatory effect, which may increase the risk of severe hypotension.

Exposure and Population Notes

An official interaction note states that co-administration may increase the blood level of Dihydroergotamine, which can heighten its hypertensive effect. The regulatory label also highlights Population-Specific Susceptibility, noting that elderly patients and individuals with marked hepatic or renal insufficiency may be more susceptible to severe orthostatic hypotension during co-administration with other vasodilating agents. Food intake does not alter the overall absorption (AUC) of the extended-release formulation.

Mechanism of Action

The NO-sGC-cGMP Molecular Cascade

Isosorbide Mononitrate functions as a prodrug, requiring cellular processes to release its active effector, Nitric Oxide ( NO). This NO selectively targets and activates the enzyme soluble Guanylyl Cyclase ( sGC) inside vascular smooth muscle cells. This initiation step triggers a cascade that significantly increases the concentration of the secondary messenger cyclic Guanosine Monophosphate ( cGMP), which results in the relaxation of the smooth muscle and dilation of the blood vessel.

Vascular Tone Modulation and Preload Reduction

The resulting vasodilation demonstrates a physiological selectivity for the venous system. This relaxation causes blood to pool peripherally, reducing the volume and pressure of blood returning to the heart, known as preload. This reduction in cardiac filling pressure lowers the heart's wall tension, resulting in a quantifiable decrease in the heart's overall oxygen consumption. The drug also contributes to improved coronary perfusion by relaxing the heart's own arteries.

Mechanistic Constraint (Tolerance)

The mechanism's physiological response is subject to a phenomenon called tachyphylaxis (tolerance), where continuous exposure leads to an attenuation of the physiological effect. Furthermore, the inherent kinetic steps of bioactivation and signaling mean the onset is not sufficiently rapid, constraining the mechanism to sustained pathway modulation due to the relative slowness of onset.

Dosage and Administration Information

How to Use Carvasin — Usage Guidelines

Proper use of Carvasin (Isosorbide Dinitrate) involves specific parameters concerning route, timing, and dosage.

Routes and Administration

Carvasin is available for both oral and sublingual administration.

  • Oral (Conventional Tablets): These are typically taken on an empty stomach, at least 30 minutes before or 2 hours after a meal. Tablets are swallowed whole with water.
  • Oral (Extended-Release): Capsules or tablets are swallowed whole without splitting, crushing, or chewing.
  • Sublingual Tablets: The tablet is placed under the tongue to dissolve completely. It is not chewed, crushed, or swallowed.

Dosing Schedule and Timing

The dosing regimen for conventional oral tablets is characterized by a daily drug-free interval of at least 14 hours. This time period, free of the medicine, is used to prevent the body from developing tolerance, which would reduce the drug's effectiveness.

For example, if taking three doses a day, they are scheduled in a way that respects this interval (e.g., morning, afternoon, and early evening). Sublingual use for expected stress is typically taken 15 minutes prior. The dose for children and teenagers has not been established in controlled clinical trials and is determined by a healthcare provider.

Missed Dose Procedure

If a dose is missed, it is taken as soon as remembered. However, if it is nearly time for the next scheduled dose, the missed dose is skipped entirely. A double or extra amount is not taken to make up for the missed dose.

Recent Clinical Evidence

Research Evidence for Angina Prophylaxis

This section summarizes the types of controlled clinical trials, such as randomized and placebo-controlled studies, that evaluated the study of this medication for the prophylactic and chronic treatment of Angina Pectoris. Research for Carvasin involves studies exploring conditions characterized by fluctuating or episodic manifestations, which is relevant in trials assessing short-term or episodic symptom patterns.

Research examined how symptoms evolved in the observed populations in short-term studies, often lasting only a few weeks. The findings describe patterns observed in these studies related to the study of this medicine in stable angina. Studies were designed to examine the pattern of outcomes related to physical discomfort during periods of heightened symptom activity.

Outcomes Monitored in Trials

In studies, the primary outcomes monitored included changes in angina attack frequency and the patient-reported use of short-acting relief medication. These outcomes reflect measures often used to monitor daily functioning or activity level in research settings. In controlled settings, studies also monitored how long participants could exercise before experiencing symptoms or showing specific changes in heart monitoring.

Durability and Research Limitations

The study of Carvasin included the general adult population with chronic stable angina, and studies monitored specific outcomes in older adults. However, data for certain groups are limited, including the study of this medicine in pediatric populations or in pregnant patients.

Most core evidence comes from trials where follow-up durations were limited, typically spanning two to six weeks. A notable limitation frequently studied is the challenge of nitrate tolerance, where research describes that the physiological response may diminish with continuous exposure. This required studies to explore specific dosing patterns used to explore mitigation of tolerance effects. Long-term effects are not fully established, and research provides context but does not determine individual predictions about long-term outcomes.

Key Studies & References

  1. Isosorbide Mononitrate Extended-Release Tablets, USP. Official Drug Label and Information

Frequently Asked Questions (FAQ)

Common questions about Carvasin (FAQ)

Q: What is the difference between Carvasin and similar nitrate drugs?

Official product information classifies Carvasin (Isosorbide Mononitrate) as a long-acting organic nitrate. This classification means the medication is intended for the prevention and sustained management of angina symptoms. This role is distinct from that of short-acting nitrates, which are generally used for immediate, acute relief.


Q: Does Carvasin affect energy levels or cause fatigue?

Regulatory safety summaries indicate that feeling unusually weak or tired (fatigue) has been reported as a side effect. This sensation is often related to the drug's action as a vasodilator, which can cause a temporary drop in blood pressure.


Q: How long do official sources indicate a person might need to take Carvasin?

According to official documents, Carvasin is indicated for the prophylactic and chronic treatment of angina symptoms. It is therefore typically used on a long-term basis as a foundational maintenance therapy, rather than for short-term use.


Q: What happens to the body when Carvasin treatment is suddenly stopped?

Official regulatory warnings describe that the abrupt cessation or sudden withdrawal of this medication should generally be avoided. This is due to the possibility that stopping suddenly could lead to a severe exacerbation or worsening of anginal symptoms.


Q: Can Carvasin be taken with over-the-counter pain relievers?

Official guidance suggests that common relievers like Paracetamol (acetaminophen) are generally consistent with use. However, official labels highlight cautionary information regarding the regular use of NSAIDs (such as ibuprofen), noting they may be associated with risks in certain heart conditions.


Q: Are there any known interactions between Carvasin and common herbal supplements?

Because herbal remedies and supplements are not regulated or tested for drug interactions in the same way as prescription medicines, official guidance highlights the need for caution. Patients are instructed to inform their healthcare provider of all supplements being taken.


Q: How does Carvasin compare to sublingual nitroglycerin in its intended use?

The official therapeutic goal for Carvasin is for the prevention and long-term control of angina episodes. This is distinct from sublingual nitroglycerin, which is a fast-acting medicine intended for the acute relief of chest pain during a sudden attack.


Q: Is Carvasin primarily used in conjunction with other cardiac treatments?

Authoritative guidance supports that this medication is commonly used as part of a comprehensive management plan for angina. It is often prescribed alongside other cardiovascular treatments, such as short-acting nitroglycerin for acute use.


Q: Does Carvasin have any known effects on mental clarity or mood?

Regulatory warnings note that side effects may include effects on the central nervous system, which could impact coordination or judgment. Symptoms such as confusion or dizziness are listed as potential effects, particularly when associated with a significant drop in blood pressure.


Q: How is the purpose of Carvasin different from a standard blood pressure medicine?

While Carvasin's mechanism of action causes vasodilation that lowers blood pressure, its primary therapeutic purpose is the prophylactic treatment of angina pectoris (chest pain). It is specifically used to prevent angina attacks, not to treat primary hypertension (high blood pressure) itself.


Q: Are there specific medical tests that are usually required before starting Carvasin?

Regulatory summaries note that for patients using the medication long-term, healthcare providers may conduct regular follow-up checks on their progress. This may include the need for certain blood tests to monitor for potential unwanted effects.


Q: Is it described in official sources that Carvasin affects vision?

Regulatory documents state that severe effects, such as a large drop in blood pressure (hypotension), may lead to other symptoms. These symptoms can potentially include blurry vision or other changes in vision.

How should Carvasin be stored and disposed of?

Carvasin (Isosorbide Mononitrate) must be stored under specific regulatory constraints to preserve its stability and effectiveness.

Official Storage and Handling

Requirement Condition
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Excursions are permitted between 15 C and 30 C.
Protection Protect from moisture and excessive heat; Do not freeze.
Container Keep in the original container and ensure it is tightly closed.
Child Safety Keep out of the reach and sight of children.

Disposal Requirements

Disposal of unused or expired Carvasin must follow local governmental regulations. The product should not be flushed down the toilet unless specifically instructed by an official authority. Guidelines recommend disposing of the product through a drug take-back program or by mixing it with an undesirable substance and sealing it in a bag before placing it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Carvasin found in:

A-Z Index: